原发肿瘤部位作为RAS野生型转移性结直肠癌患者治疗选择驱动因素:随机试验的系统综述与汇总分析
该系统综述与汇总分析纳入5项随机试验共2739例RAS野生型转移性结直肠癌患者,左半77%、右半23%。左半患者使用抗EGFR药物与更高的客观缓解率(74% vs 62%,OR=1.77,95%CI 1.39-2.26-0.88,p<0.0001)和更长的总生存期(HR=0.77,95%CI 0.68-0.88,p<0.0001)相关,无进展生存期无显著延长(HR=0.92,p=0.19)。右半患者使用贝伐珠单抗与更长的无进展生存期相关(HR=1.36,95%CI 1.12-1.65,p=0.002),总生存期无显著延长(HR=1.17,p=0.14)。原发肿瘤部位与治疗组在ORR(p=0.02)、PFS(p=0.0004)和OS(p=0.001)方面存在显著交互作用。根治性切除率按治疗和部位未见差异。
要点
- 左半RAS野生型mCRC:抗EGFR药物与更高的ORR(74% vs 62%,OR=1.77,95%CI 1.39-2.26-0.88,p<0.0001)和更长的OS(HR=0.77,95%CI 0.68-0.88,p<0.0001)相关。
- 右半RAS野生型mCRC:贝伐珠单抗与更长的PFS相关(HR=1.36,95%CI 1.12-1.65,p=0.002),OS无显著延长(HR=1.17,p=0.14)。
- 原发肿瘤部位与治疗组在ORR(p=0.02)、PFS(p=0.0004)和OS(p=0.001)方面存在显著交互作用。
核心结论
- 本汇总分析证实原发肿瘤部位在RAS野生型mCRC患者一线治疗选择中的作用,作者强烈推荐左半肿瘤使用抗EGFR药物,右半肿瘤优先使用贝伐珠单抗。
研究设计与样本
- 系统检索II期和III期随机试验,比较双药化疗联合抗EGFR或贝伐珠单抗作为RAS野生型mCRC患者一线治疗的研究。
- 纳入5项试验(PEAK、CALGB/SWOG 80405、FIRE-3、PARADIGM和CAIRO5),共2739例患者,左半77%、右半23%。
- 采用两阶段分析,合并随机效应和固定效应模型,分析总生存期(OS)、无进展生存期(PFS)、客观缓解率(ORR)和根治性切除率,并分析部位与治疗效应的交互作用。
主要发现
- 左半mCRC患者中,抗EGFR药物与更高的ORR相关(74% vs 62%,OR=1.77,95%CI 1.39-2.26-0.88,p<0.0001),与更长的OS相关(HR=0.77,95%CI 0.68-0.88,p<0.0001),PFS无显著延长(HR=0.92,p=0.19)。
- 右半mCRC患者中,贝伐珠单抗与更长的PFS相关(HR=1.36,95%CI 1.12-1.65,p=0.002),OS无显著延长(HR=1.17,p=0.14)。
- 亚组分析证实原发肿瘤部位与治疗组在ORR(p=0.02)、PFS(p=0.0004)和OS(p=0.001)方面存在显著交互作用。
- 根治性切除率按治疗和部位未见差异。
关键数值与推荐
- 左半mCRC:抗EGFR药物 vs 贝伐珠单抗,ORR 74% vs 62%(OR=1.77,95%CI 1.39-2.26-0.88,p<0.0001),OS HR=0.77(95%CI 0.68-0.88,p<0.0001),PFS HR=0.92(p=0.19)。
- 右半mCRC:贝伐珠单抗 vs 抗EGFR药物,PFS HR=1.36(95%CI 1.12-1.65,p=0.002),OS HR=1.17(p=0.14)。
- 交互作用:ORR p=0.02,PFS p=0.0004,OS p=0.001。
- 作者强烈推荐左半肿瘤使用抗EGFR药物,右半肿瘤优先使用贝伐珠单抗。
临床怎么用
- 作者强烈推荐左半RAS野生型mCRC患者一线使用抗EGFR药物,右半患者优先使用贝伐珠单抗。
- 原发肿瘤部位应作为RAS野生型mCRC患者一线治疗选择的重要依据。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Retrospective subgroup analyses of previous trials in the first-line therapy of RAS wt metastatic colorectal cancer (mCRC) suggested a predictive impact of primary tumour side on the efficacy of anti-epidermal growth factor receptor (EGFR) agents. Recently, new head-to-head trials of doublets/bevacizumab versus doublets/anti-EGFR, PARADIGM and CAIRO5 were presented. PATIENTS AND METHODS: We searched for phase II and III trials comparing doublet chemotherapy plus an anti-EGFR or bevacizumab as the first-line treatment for RAS wt mCRC patients. Overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and radical resection rate result in the overall study populations and, according to the primary side, were pooled together in a two-stage analysis with random effects and fixed effect models. The interaction between sidedness and treatment effect was then analysed. RESULTS: We identified five trials (PEAK, CALGB/SWOG 80405, FIRE-3, PARADIGM and CAIRO5), including 2739 patients, 77% left- and 23% right-sided. Among patients with left-sided mCRC, the use of anti-EGFRs was associated with higher ORR (74% versus 62%, OR = 1.77 [95% confidence interval {CI} 1.39-2.26-0.88], p < 0.0001), longer OS (hazard ratio [HR] = 0.77 [95% CI 0.68-0.88], p < 0.0001) and not significantly longer PFS (HR = 0.92, p = 0.19). Among patients with right-sided mCRC, the use of bevacizumab was associated with longer PFS (HR = 1.36 [95% CI 1.12-1.65], p = 0.002) and not significantly longer OS (HR = 1.17, p = 0.14). A subgroup analysis confirmed a significant interaction effect between the primary tumour side and treatment arm in terms of ORR (p = 0.02), PFS (p = 0.0004) and OS (p = 0.001). No differences in the radical resection rate were found according to treatment and sidedness. CONCLUSIONS: Our updated metanalysis corroborates the role of the primary tumour location in the choice of the upfront therapy for RAS wt mCRC patients, leading to strongly recommend anti-EGFRs in left-sided tumours and to prefer bevacizumab in the right-sided.
引用
- Rossini D, Boccaccino A, Carullo M, et al. Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials. Eur J Cancer. 2023. PMID: 36913832. doi:10.1016/j.ejca.2023.02.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。